Last reviewed · How we verify
NCT05451004: SELECT
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Phase 3 trial testing Lymphatic Mapping with SPECT-CT in Oropharyngeal Cancer in 510 participants. Currently enrolling.
30 August 2030
Quick facts
| Lead sponsor | Canadian Cancer Trials Group |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 510 |
| Start date | 10 February 2023 |
| Primary completion | 30 August 2030 |
| Estimated completion | 30 August 2031 |
| Sites | 36 locations across Canada, United States |
Drugs / interventions tested
- Lymphatic Mapping with SPECT-CT
- Ipsilateral and Contralateral Neck
Conditions studied
- Oropharyngeal Cancer — all drugs for Oropharyngeal Cancer →
Sponsor
Canadian Cancer Trials Group — full company profile →
Who can join
18 and older, any sex, with Oropharyngeal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT), compared to the usual treatment when radiotherapy is given to both sides of the neck?
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
De-escalation of head-and-neck cancer radiotherapy: balancing cure and side effects.
Duprez F, Daisne JF, Longton E, Nuyts S. · · 2026 · PMID 42038372 · DOI 10.3389/fonc.2026.1798321
Verify or expand the search:
- PubMed search for NCT05451004
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Oropharyngeal Cancer
Currently open trials in the same condition.
- NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
- NCT06446713 — PIRATES: Image-guided Hyper-fractioned Dose-escalation With Proton Therapy for Head and Neck Cancer · Phase 1 · recruiting
- NCT06747390 — Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery · Phase 1 · recruiting
- NCT05363709 — BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients · Phase 2 · active not recruiting
- NCT05862792 — Liposomal Bupivacaine and Transoral Robotic Surgery · recruiting
Other Canadian Cancer Trials Group trials
Trials by the same sponsor.
- NCT07390435 — Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials · not yet recruiting
- NCT07297667 — GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours · Phase 1 · not yet recruiting
- NCT06630273 — Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated With Immuno-Oncotherape · not yet recruiting
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07341191 — Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05451004 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Canadian Cancer Trials Group
- Last refreshed: 14 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05451004.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing